Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Addex Therapeutics's share price for the quarter that ended in Mar. 2026 was €5.6. Addex Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 0.99 Mil. Therefore, Addex Therapeutics's market cap for the quarter that ended in Mar. 2026 was €5.57 Mil.
Addex Therapeutics's quarterly market cap
declined
from Sep. 2025 (€7.72 Mil) to Dec. 2025 (€6.19 Mil) and
declined
from Dec. 2025 (€6.19 Mil) to Mar. 2026 (€5.57 Mil).
Addex Therapeutics's annual market cap
increased
from Dec. 2023 (€4.01 Mil) to Dec. 2024 (€5.33 Mil) and
increased
from Dec. 2024 (€5.33 Mil) to Dec. 2025 (€6.19 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Addex Therapeutics's Enterprise Value for Today is €5.42 Mil.
Addex Therapeutics (FRA:APE1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Addex Therapeutics Market Cap Related Terms
Addex Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Addex Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APE1 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Addex Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Addex Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Addex Therapeutics (FRA:APE1) has a Market Cap of €6.33 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Addex Therapeutics and its competitors. According to the industry distribution chart, Addex Therapeutics ranks #1231 out of 1428 companies in the Biotechnology industry, placing it in the top 86.2%.
Is Addex Therapeutics' Market Cap too high?
Addex Therapeutics' current Market Cap is €6.33 Mil. Based on the distribution chart, Addex Therapeutics ranks #1231 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #1231 out of 1428 companies for Market Cap. This places Addex Therapeutics in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Addex Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Addex Therapeutics's current Market Cap is €6.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Market Cap of €6.33 Mil. The stock's GF Value™ is €1.14, compared to a current price of €4.98 — trading 336.8% above its estimated fair value. The current Market Cap is €6.33 Mil. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Market Cap is €6.33 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?
Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued.
The current stock price of €4.98 is trading 336.8% above its estimated GF Value™ of €1.14.
Key valuation signals for FRA:APE1:
Market Cap: €6.33 Mil
GF Value™: €1.14 vs. price of €4.98 (336.8% above fair value)
No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score
Get the complete analysis for FRA:APE1
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE1 has been successfully added to your 
